Skip to main content
SpringerLink
Log in

Diagnosis and Differential Diagnosis of Primary Hyperparathyroidism

  • Chapter
Primary, Secondary and Tertiary Hyperparathyroidism

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 1183 Accesses

Abstract

Nowadays, the diagnosis of primary hyperparathyroidism (pHPT) is more precocious if compared to the past. It makes it possible to identify patients with few symptoms, regardless of the clinical features generally represented by the later disease complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. AACE/AAES Task Force on Primary Hyperparathyroidism (2005) The American Association of Clinical Endocrinologists and The American Association of Endocrine Surgeons Position Statement on the Diagnosis and Management of Primary Hyperparathyroidism. Endocr Pract 11:50–54

    Google Scholar 

  2. Cusano NE, Silverberg SJ, Bilezikian JP (2013) Normocalcemic primary hyperparathyroidism. J Clin Densitom 16:33–39

    Article  PubMed Central  PubMed  Google Scholar 

  3. Glendenning P (2003) Diagnosis of primary hyperparathyroidism: controversies, practical issues and the need for Australian guidelines. Intern Med J 33:598–603

    Article  CAS  PubMed  Google Scholar 

  4. Eastelle R, Arnold A, Brandi ML et al (2009) Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Third International Workshop. J Clin Endocrinol Metab 94:340–350

    Article  Google Scholar 

  5. Eastell R, Brandi ML, Costa AG et al (2014) Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99:3570–3579

    Article  CAS  PubMed  Google Scholar 

  6. Endres DB (2012) Investigation of hypercalcemia. Clin Biochem 45:954–963

    Article  CAS  PubMed  Google Scholar 

  7. Nordenstrom E, Katzman P, Bergenfelz A (2011) Biochemical diagnosis of primary hyperparathyroidism: Analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem 44:849–852

    Article  CAS  PubMed  Google Scholar 

  8. Ladenson JH (1991) Calcium determination in primary hyperparathyroidism. J Bone Mineral Res 6(Suppl 2):S33-S41

    CAS  Google Scholar 

  9. Woo S, Song H, Song KE et al (2006) A case report of familial benign hypocalciuric hypercalcemia: a mutation in the calcium-sensing receptor gene. Yonsei Med J 47:255–258

    Article  PubMed Central  PubMed  Google Scholar 

  10. Bergenfelz A, Valdermarsson S and Ahren B (1993) Suppression by calcium of serum levels of intact parathyroid hormone in primary hyperparathyroidism. Hormone Res 39:146–151

    Article  CAS  PubMed  Google Scholar 

  11. Khosla S, Ebeling PR, Firek AF et al (1993) Calcium infusion suggests a set-point abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 76:715–720

    CAS  PubMed  Google Scholar 

  12. Nygren P, Gylfe E, Larsson R et al (1998) Modulation of the Ca2+-sensing function of parathyroid cells in vitro and hyperparathyroidism. Biochim Biophys Acta 968:253–260

    Article  Google Scholar 

  13. Farnebo F, Enberg U, Grimelius L et al (1997) Tumor-specific decreased expression of calcium sensing receptor messenger ribonucleic acid in sporadic primary hyperparathyroidism. J Clin Endocrinol Metab 82:3481–3486

    CAS  PubMed  Google Scholar 

  14. Corbetta S, Mantovani G, Lania A et al (2000) Calcium-sensing receptor expression and signaling in human parathyroid adenomas and primary hyperplasia. Clin Endocrinol (Oxf) 52: 339-348

    Article  CAS  Google Scholar 

  15. Yano S, Sugimoto T, Tsukamoto T et al (2003) Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. Eur J Endocrinol 148:403–411

    Article  CAS  PubMed  Google Scholar 

  16. Mizunashi K, Furukawa Y, Goto MM (1998) Ratio of baseline level/maximum level of serum PTH in pseudohypoparathyroidism and primary hyperparathyroidism. Calcif Tissue Int 62:991–998

    Google Scholar 

  17. Titon I, Cailleux-Bounacer A, Basuyau JP et al (2007) Evaluation of a standardized short-time calcium suppression test in healthy subjects: interest for the diagnosis of primary hyperparathyroidism. Eur J Endocrinol 157:351–357

    Article  CAS  PubMed  Google Scholar 

  18. Zhao L, Zhang MJ, Zhao HY et al (2011) PTH inhibition rate is useful in the detection of early-stage primary hyperparathyroidism. Clin Biochem. 44(10-11):844–848

    Article  CAS  PubMed  Google Scholar 

  19. Hagag P, Revet-Zak I, Hod N et al (2003) Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest 26:327–332

    Article  CAS  PubMed  Google Scholar 

  20. Lips P, Netelenbos JC, van Doorn L et al (1991) Stimulation and suppression of intact parathyroid hormone (PTH1-84) in normal subjects and hyperparathyroid patients. Clin Endocrinol (Oxf) 35:35–40

    Article  CAS  Google Scholar 

  21. Dawson-Hughes B, Harris SS, Dallal GE (1997) Plasma calcidiol, season, and serum parathyroid hormone concentrations in healthy elderly men and women. Am J Clin Nutr 65:67–71

    CAS  PubMed  Google Scholar 

  22. Steingrimsdottir L, Gunnarsson O, Indridason OS et al (2005) Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA 294:2336–2341

    Article  CAS  PubMed  Google Scholar 

  23. Drüeke TB (2000) Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol 11:1141–1152

    PubMed  Google Scholar 

  24. Wermers RA, Kearns AE, Jenkins GD et al (2007) Incidence and clinical spectrum of thiazideassociated hypercalcemia. Am J Med 120:e9-e15

    Article  PubMed  Google Scholar 

  25. Pickleman JR, Straus FH, Forland M et al (1969) Thiazide induced parathyroid stimulation. Metabolism 18:867–873

    Article  CAS  PubMed  Google Scholar 

  26. Yacobi-Bach M, Serebro M, Greenman Y et al Letter to the Editor: Thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism. J Clin Endocrinol Metab 100:L27-L28

    Google Scholar 

  27. Harris ST, Gertz BJ, Genant HK et al (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399–1406

    CAS  PubMed  Google Scholar 

  28. Chennuru S, Koduri J, Bauman MA et al (2008) Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J 38:635–637

    Article  CAS  PubMed  Google Scholar 

  29. Maalouf NM, Heller HJ, Odvina CV et al 2006 Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48–53

    Article  PubMed  Google Scholar 

  30. Richmond BK (2005) Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy. Am Surg 71:872–873

    PubMed  Google Scholar 

  31. Chennuru S, Koduri J, Bauman MA (2008) Risk factors for symtomatic hypocalcemia complicating treatment with zoledronic acid. Intern Med J 38:635–637

    Article  CAS  PubMed  Google Scholar 

  32. Giusti CF, Amorim SR, Guerra RA et al (2012) Endocrine disturbances related to the use of lithium. Arq Bras Endocrinol Metabol 56:153–158

    Article  PubMed  Google Scholar 

  33. Saunders BD, Saunders EFH, Gauger PG (2009) Lithium therapy and hyperparathyroidism: an evidence-based assessment. World J Surg 33:2314–2323

    Article  PubMed  Google Scholar 

  34. Szalat A, Mazeh H, Freund HR (2009) Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 160:317–323

    Article  CAS  PubMed  Google Scholar 

  35. Skandarajah AR, Palazzo FF, Henry JF et al (2011) Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy. World J Surg 35:2432–2439

    Article  PubMed  Google Scholar 

  36. Anastasilakis AD, Toulis KA, Polyzos SA et al (2012) Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 8:295–306

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Pierroz DD, Bonnet N, Baldock PA et al (2010) Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL. J Biol Chem 285:28164–28173

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066

    Article  CAS  PubMed  Google Scholar 

  39. Makras P, Polyzos S, Papatheodorou A et al (2013) Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf) 79:499–503

    Article  CAS  Google Scholar 

  40. Thakker RV (2004) Diseases associated with the extracellular calcium-sensing receptor. Cell Calcium 35:275–282

    Article  CAS  PubMed  Google Scholar 

  41. Tfelt-Hansen J, Brown EM (2006) The calcium-sensing receptor in hereditary disorders of calcium homeostasis. Clin Cases Miner Bone Metab 3:150–161

    Google Scholar 

  42. Christensen SE, Nissen PH, Vestergaard P et al (2008) Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf) 69:713–720

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, University of Turin, Turin, Italy

    Fabio Orlandi

Authors
  1. Fabio Orlandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Federico Arecco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Corvisieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilaria Messuti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabio Orlandi .

Editor information

Editors and Affiliations

  1. Department of Surgical Sciences, University of Turin, Turin, Italy

    Guido Gasparri  & Michele Camandona  & 

  2. Department of Surgery, Città della Salute e della Scienza University Hospital, Turin, Italy

    Nicola Palestini

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Italia

About this chapter

Cite this chapter

Orlandi, F., Arecco, F., Corvisieri, S., Messuti, I. (2016). Diagnosis and Differential Diagnosis of Primary Hyperparathyroidism. In: Gasparri, G., Palestini, N., Camandona, M. (eds) Primary, Secondary and Tertiary Hyperparathyroidism. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5758-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5758-6_7

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5757-9

  • Online ISBN: 978-88-470-5758-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation